Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx ELECTRONIC TRACING ELIGIBLE FOR FUNDS IN 1993 HHS APPROPRIATIONS

Executive Summary

Rx ELECTRONIC TRACING ELIGIBLE FOR FUNDS IN 1993 HHS APPROPRIATIONS legislation, which President Bush signed into law Oct. 6. The funding measure (HR 5677) appropriates $1 mil. in fiscal 1993 and for demonstration projects on electronic prescription drug billing and information management. The Senate Appropriations Committee report on HR 5677 stipulates that "where possible, the demos should be designed to facilitate and assist statewide and federal efforts to address illegal drug diversion and to improve prescribing practices." The committee said the Health Care Finance Administration should "support research and demonstration projects designed to enable a speedier and more successful move to a national uniform electronic billing and data system." Up to $10 mil. should be spent on the demonstration projects over the program's lifetime, it says. The provision reflects legislation (HR 5051) introduced by Rep. Stark (D-Calif.) ("The Pink Sheet" May 4, In Brief) to provide for demonstration projects on automated recordkeeping of the prescribing and dispensing of prescription drug products. However, Stark's bill specifically targeting Schedules II-IV controlled substances would have provided $20 mil. in the first year to fund projects in 10 states. HR 5677 does not require testing in any particular number of states and does not specify tracing of controlled substances.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel